PhD Scientific Days 2025

Neurosciences

Comparative study of cerebrospinal fluid, serum, morphological, and EEG biomarkers of Alzheimer’s disease and determination of their practical applications.

Előadó neve

Dr. Miklos Nyerges

Neptun code

i0se4z

Előadó munkahelye

Semmelweis University - Center of Neurosurgery and Neurointervention, Neurology Department

Előadó telefonszáma

06 30 900 79 63

Előadó e-mail címe

miklos.nyerges139@gmail.com

Az előadás címe

Comparative study of cerebrospinal fluid, serum, morphological, and EEG biomarkers of Alzheimer’s disease and determination of their practical applications.

Szerző(k) neve és munkahelye

Dr. Miklos Nyerges¹, Prof. Dr. Anita Kamondi², Dr. András Horváth³, Krisztián Kovács⁴, Prof. Dr. Barna Vásárhelyi⁴, Balázs Sándor⁵

1: Semmelweis University - Center of Neurosurgery and Neurointervention, Neurology Department
2: Semmelweis University - Center of Neurosurgery and Neurointervention, Neurology Department ; National Institute of Psychiatry and Addictology
3: Neurocognitive Research Centre
4: Semmelweis University - Department of Laboratory Medicine
5: University of Debrecen

Bemutatás módja

Szóbeli

Szekció

Neurosciences

Language of the presentation

English

Preferred session

Neurosciences

Összefoglaló szövege

The number of people living with dementia globally is increasing significantly, posing major challenges to healthcare systems worldwide.
According to estimates, by 2030, the number of people living with dementia will reach 78 million globally. The most common form of dementia is Alzheimer’s disease (AD). Early diagnosis of these patients and initiating therapy in the early stages of the disease can help slow its progression and prolong the years spent with relatively mild symptoms.
In terms of AD pathomechanism, beta-amyloid plaques accumulate in the extracellular space of the central nervous system, and neurofibrillary tangles composed of tau proteins appear intracellularly. In recent years, several biomarkers have been introduced for diagnosing Alzheimer's disease using different techniques, all aiming to detect the proteins that are formed during the development of these pathological changes.
Tau-PET imaging of brain tissue has very high predictive value and is an excellent diagnostic method. It is comparable to the quantitative analysis of phosphorylated tau proteins and beta-amyloid proteins in cerebrospinal fluid (CSF). However, tau-PET is very expensive and not available in many countries, including Hungary.
To provide the possibility for biomarker-based diagnosis of AD 3 years ago we introduced a CSF p-tau and beta-amyloid test in Hungary that matches the accuracy of international standards. However, due to the discomfort associated with lumbar puncture and the need to screen large numbers of patients, there is a growing need for a reliable blood test using plasma samples.
To overcome these difficulties we introduced an ELISA-based serum beta-amyloid biomarker test in Hungary in 2024.
In the current phase of our research, we enrolled 125 patients. CSF samples were collected from 113 of them, and serum tests were performed in 50 cases. We compared these test results to each other, as well as to cognitive test results, brain MRI findings, spike activity detected in long-term EEG recordings and chemical laboratory tests.
Our data revealed that the newly introduced CSF test has a very good positive and negative predictive value for AD diagnosis based on clinical diagnostic criteria. Plasma amyloid tests yielded less consistent results which might be explained with methodological differences.

University

Semmelweis University

Supervisor

Prof. Dr. Anita Kamondi

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies before complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

9035

Start

10:00

End

10:15